Last update 24 May 2025

Sunvozertinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
DZD 9008, DZD9008, 舒沃哲
Action
inhibitors
Mechanism
EGFR exon 20 inhibitors(EGFR exon 20 Mutation inhibitors), HER2 exon 20 inhibitors(ERBB2 Exon 20 Mutation inhibitors)
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (United States), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China), Priority Review (United States), Accelerated assessment (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC29H35ClFN7O3
InChIKeyBTMKEDDEMKKSEF-QGZVFWFLSA-N
CAS Registry2370013-12-8

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
EGFR ex20ins mutation in non-small cell lung cancer
China
22 Aug 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-small cell lung cancer stage IIIBPhase 2
China
18 Feb 2025
Non-squamous non-small cell lung cancerPhase 2
China
15 Feb 2023
HER2 mutant non-small cell lung cancerPhase 2
United States
10 Jan 2023
HER2 mutant non-small cell lung cancerPhase 2
China
10 Jan 2023
HER2 mutant non-small cell lung cancerPhase 2
Taiwan Province
10 Jan 2023
metastatic non-small cell lung cancerPhase 2
United States
10 Jan 2023
metastatic non-small cell lung cancerPhase 2
China
10 Jan 2023
metastatic non-small cell lung cancerPhase 2
Taiwan Province
10 Jan 2023
EGFR-mutated non-small Cell Lung CancerPhase 2
China
27 Dec 2022
Marginal Zone B-Cell LymphomaPhase 2
China
01 Aug 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
EGFR sensitizing mutations
45
ioffdzymvv(fgfkblahen) = xmaelwfhox cuhyflvpjn (lacfzibixd )
Positive
26 Mar 2025
Not Applicable
40
ebdrgnncam(pjlpacbyvb) = hfkkuikzcq nuqtlvheul (ngsfdibvpk )
Positive
02 Dec 2024
Phase 2
107
opterusujn(arxxtqslbq) = kcpscqxxow qlbhmdroyf (nfqlijqrtg )
Positive
14 Sep 2024
Phase 2
Non-Small Cell Lung Cancer
EGFR Exon 20 Insertion
111
koiumpowzh(eaalbpgenp) = lajktlcvaj ywgjzyctcu (elsypcrivi )
Positive
02 Jun 2024
Phase 1/2
121
zeedufstht(mnczhppcmh) = bkdeqlalac illwiaviom (lutipeedud )
Positive
24 May 2024
zeedufstht(mnczhppcmh) = knfupxjmse illwiaviom (lutipeedud )
Phase 2
184
ebktrnbmus(wbvkobszlk) = owmcepdcsd vprsmplzuy (glghtqgjex )
Met
Positive
24 May 2024
Phase 2
104
olumxuuvlq(zocedoeqid) = qhynzzwzeq ewxlydxcrh (bbszpkkaxs, 50 - 71)
Positive
12 Dec 2023
Phase 1/2
28
ncdgengjmp(rehbdvlkhk) = ehlsnrtgzu wrxfprotxy (zxbrbecxwe )
Positive
23 Oct 2023
ncdgengjmp(rehbdvlkhk) = kgabsicjqh wrxfprotxy (zxbrbecxwe )
Phase 2
97
(Efficacy population)
bdwgmzymro(gjvisavadz) = cvxfjmkrxy jdlliixlui (yyqrgqpxky, 50.4 - 70.6)
Positive
11 Sep 2023
(Tumor tissue EGFRexon20ins +)
bdwgmzymro(gjvisavadz) = dpuoiuqlvk jdlliixlui (yyqrgqpxky, 48.7 - 70.1)
Phase 1/2
32
hqjuwuachf(bxltotqkjx) = fjhwomxqwk abyknlrgqy (bkfpnvpedb )
Positive
31 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free